Technology | Fusion Imaging Software | January 03, 2017

MIM Symphony MRI Fusion Biopsy Software Integrates With BK3000 Ultrasound System

New bkFusion solution will allow more accurate and reliable biopsy results than ultrasound-only transrectal biopsy

MIM Software, BK Ultrasound, bkFusion, MRI Fusion Biopsy System, prostate cancer, RSNA 2016

January 3, 2017 —  MIM Software Inc. announced in November the commercial introduction of its MRI (magnetic resonance imaging) Prostate Fusion Software as a fully integrated software on BK Ultrasound’s premium bk3000 ultrasound system. The global launch of this solution for prostate biopsy, bkFusion, was developed in partnership between the companies.

bkFusion is built on MIM Software’s multi-modality image fusion capabilities. In creating bkFusion, MIM Software leveraged its patented Predictive Fusion technology for MRI prostate fusion during biopsy. Predictive Fusion “reslices” and pre-aligns the MRI images to correspond to the prostate’s orientation during the biopsy and then fuses them to the ultrasound images at the time of biopsy, saving time during the procedure. This advancement in MRI targeting assists the practitioner in achieving a higher prostate cancer detection rate when compared to traditional ultrasound-only transrectal biopsy. Patients will benefit from a more accurate and reliable biopsy when prostate cancer is present.

The bkFusion solution, consisting of the bk3000 ultrasound system along with the E14C4t Prostate Triplane transducer, will provide an MRI Fusion Biopsy System with the smallest footprint in the industry, according to the companies. The bk3000 fits easily into any office space and because bkFusion is completely integrated on the ultrasound system, no additional bulky equipment or setup time is required. The system communicates easily with radiology departments, accessing the MRI images via picture archiving and communication system (PACS) or a secure cloud platform. Alternatively, with the BK Flex Focus ultrasound product line, BK Ultrasound will offer a laptop-based bkFusion application. Both the integrated application and laptop version will provide the same user interface, workflow and reporting.

MIM will continue to develop and distribute its MIM Symphony Dx advanced MRI prostate visualization and analysis software for radiologists. Software features include prostate MRI review, linking, contouring and reporting capabilities. MIM Symphony Dx includes tools for quantitative longitudinal analysis, linking of biopsy results and locations with MR, and sophisticated reporting. MIM Symphony Dx and bkFusion share a common platform and will allow seamless communication either directly, via MIMcloud, or through external drives.

BK Ultrasound will distribute bkFusion for use with its bk3000 and Flex Focus ultrasound systems in the United States. BK Ultrasound has undertaken registration globally and will distribute the solutions through its global network.

For more information: www.mimsoftware.com

Related Content

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health S

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health System

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Card...
A sonographer at Northwestern Memorial Hospital using the Caption Health AI to optimize ultrasound imaging.

A sonographer at Northwestern Memorial Hospital using the Caption Health AI to optimize ultrasound imaging.

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Heal
Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020
October 27, 2020 – Magn...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...